How to Buy Acumen Pharmaceuticals Stock
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
Acumen Pharmaceuticals stock last closed at $4.81, down 0.82% from the previous day, and has increased 38.22% in one year. It has overperformed other stocks in the Biotechnology industry by 0.37 percentage points. Acumen Pharmaceuticals stock is currently +51.97% from its 52-week low of $3.17, and -56.15% from its 52-week high of $10.97.
There are currently 41.03M shares of ABOS outstanding. The market cap of ABOS is $197.33M. In the past 24 hours, 82,003 ABOS shares were traded.
How to Buy Acumen Pharmaceuticals Stock
Wondering how to invest in Acumen Pharmaceuticals stock? Here's how.
- Figure out where to buy Acumen Pharmaceuticals stock: You need to pick an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Acumen Pharmaceuticals stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Pick your payment method and add your details.
- Evaluate Acumen Pharmaceuticals stock: The Acumen Pharmaceuticals ticker symbol is ABOS. Is Acumen Pharmaceuticals stock a good investment? Should you buy shares of ABOS? How do ABOS's underlying business fundamentals look? Do top analysts think Acumen Pharmaceuticals is a good buy? Why has ABOS's stock price moved recently? (Hint: Our stock analysis website can help you figure out if ABOS is a good stock to buy).
- Place your ABOS trade: Decide if you will purchase ABOS shares at the current market price or use a limit order to purchase ABOS stock at a particular price.
- Get the latest scoop on your ABOS position: Create a watchlist to important updates regarding your new investment in Acumen Pharmaceuticals stock.
Step 1: Figure out where to buy Acumen Pharmaceuticals stock
You will need a brokerage account to access the NASDAQ market and buy ABOS shares.
Our favorite brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global financial markets: From Technology to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, you'll need to fill out some personal information so you are able to invest in ABOS stock today.
How to Create a New Account on eToro
- Click here to get started.
- Provide your personal data to open your new brokerage account.
- Send your details by clicking the "Create Account" button.
Step 3: Put funds into your brokerage account
Now that you have created your account on the best stock app to use, you need to deposit funds:
Check out the walkthrough below to see the process of transferring money into your investment account.
Step 4: Evaluate Acumen Pharmaceuticals stock
After you have identified the best place to buy Acumen Pharmaceuticals stock, it's absolutely critical to analyze their stock before you invest, so you truly wrap your head around the risk and upside.
Acumen Pharmaceuticals shares at a glance
ABOS Zen Score
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on ABOS's stock page.
What is the fair value of ABOS stock?
Investors use many financial metrics, analyses, models, and charts to gauge ABOS's true value.
Using relative valuations metrics:
- ABOS may be undervalued based on its P/B ratio of 1.1x, relative to Biotechnology industry P/B ratio of 5.18x
You can do additional valuation research on ABOS's stock here.
A look at ABOS Cashflows and Balance Sheet
Pros:
- ABOS has cash burn of 37181000. It has sufficient cash and short-term investments to cover this for at least one year.
- ABOS has $140.41M in cash and short term investments. This is sufficient to cover its annual cash burn of $37.18M.
- ABOS has a low debt to equity ratio of 0.05.
- There are more short-term assets than long-term liabilities on the ABOS balance sheet.
- There are more short-term assets than short-term liabilities on the ABOS balance sheet.
Is Acumen Pharmaceuticals stock a Buy, Hold, or Sell, according to analysts?
Out of 3 Wall Street analysts who give recommendations on ABOS, the consensus analyst rating on ABOS is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest ABOS Analyst Forecasts
Pete Stavropoulos, a bottom 13% analyst from Cantor Fitzgerald initiates coverage on ABOS with a strong buy rating and announces their ABOS price target of $13.00, on May 18, 2023.
Judah Frommer, a bottom 20% analyst from Credit Suisse maintains ABOS with a buy rating and lowers their ABOS price target from $16.00 to $13.00, on Mar 28, 2023.
Andrew Fein, a top 13% analyst from HC Wainwright & Co. reiterates ABOS with a buy rating and maintains their ABOS price target from $15.00 to $15.00, on Mar 28, 2023.
You can dig deeper into what analysts are projecting on the Acumen Pharmaceuticals stock forecast page.
ABOS Momentum
Who is buying/selling ABOS?
In the past 12 months, insiders at ABOS have bought more shares than they have sold.
Matt Zuga, CFO and Chief Business Officer of ABOS, was the latest ABOS insider to buy. They bought $59,500.00 worth of ABOS stock on Dec 29, 2022.
Get more info about who owns ABOS stock here.
Does ABOS stock generate passive income?
No, Acumen Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Place your ABOS trade
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount, place a limit order.
Click the Open button and your broker will place the order.
If you need additional assistance investing in stocks on eToro, click the helpful video below:
Step 6: Get the latest scoop on your ABOS position
Now that you own some shares in ABOS, you'll want to keep up with your investment.
Create a watchlist to get the latest updates about your ABOS stock.
ABOS Feed
How to Buy Stock in Acumen Pharmaceuticals
To summarize, here are the 6 steps you need to take to buy Acumen Pharmaceuticals stock right now:
- Figure out where to buy Acumen Pharmaceuticals stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Evaluate Acumen Pharmaceuticals stock
- Place your ABOS trade
- Get the latest scoop on your ABOS position
If you need a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your investment in Acumen Pharmaceuticals, get started below.
Trending Articles
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.